Source comparison
BPC-157 for Bulging Disc Research: Evidence Comparison
Animal Model (Rat Disc Degeneration) Controlled, mechanically induced disc injury, 10 mcg/kg daily × 4 weeks 12% disc height loss vs 31% control; 40–50% reduction in IL-6, TNF-alpha; preserved proteoglycan content Rat healing biology differs from humans; short
This comparison does not assign a generated winner or score.
- Animal Model (Rat Disc Degeneration)
- Controlled, mechanically induced disc injury, 10 mcg/kg daily × 4 weeks
- 12% disc height loss vs 31% control; 40–50% reduction in IL-6, TNF-alpha; preserved proteoglycan content
- Rat healing biology differs from humans; short treatment window; injury model doesn't replicate herniation biomechanics
- Promising mechanism, poor translatability
- In Vitro Fibroblast Studies
- Human fibroblast cultures treated with BPC-157 at 1–10 mcg/mL
- 340% increase in fibroblast proliferation; upregulated collagen type I synthesis; reduced MMP-2 expression
- Cell culture lacks tissue complexity, biomechanical load, immune system interaction
- Supports mechanistic hypothesis only
- Human Case Reports
- Self-administered subcutaneous injection, 250–500 mcg daily, 8–12 weeks
- Variable pain reduction; no imaging confirmation of structural disc changes
- No controls, placebo effect likely, concurrent interventions not controlled
- Anecdotal. Not evidence
- Comparative Peptide Research (TB-500, GHK-Cu)
- Cross-study analysis of tissue repair peptides in soft tissue models
- BPC-157 showed faster collagen remodeling than TB-500 in tendon injury; GHK-Cu had superior anti-inflammatory profile
- Different injury models, different endpoints. Direct comparison unreliable
- BPC-157 strongest for structural repair